Literature DB >> 28211799

Increased expression of long non-coding RNA GLIDR in prostate cancer.

Yingyi Zhang1,2, Zhe Kong2,2, Yalong Zhang2, Wenhua Huang2, Hai Wu2, Xuechao Wan2, Yao Li2.   

Abstract

Prostate cancer (PCa) was one of the most common cancers in males in China. Long non-coding RNAs (lncRNA), a class of non-coding RNAs with more than 200 nucleotides, played key roles in the progression of prostate cancer. GLIDR, a novel long intergenic ncRNA, was found to be upregulated in tumors compared to normal tissues by using publically databases. In the clinical validation cohort, our results showed GLIDR was significantly up-regulated in prostate cancer samples and cell lines. To explore the potential functions of the GLIDR, we constructed gene co-expression networks and applied GO analysis. Our analysis revealed that GLIDR was involved in the regulation of translational elongation, transcription, rRNA processing, RNA splicing, signal transduction, and cell adhesion. Furthermore, a GLIDR-mediated ceRNA network in prostate cancer was also identified. We believed that this study still provided some clues in exploring new therapeutic and prognostic targets for prostate cancer.

Entities:  

Keywords:  GLIDR; Prostate cancer; ceRNA; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28211799     DOI: 10.3233/CBM-160166

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  2 in total

1.  LncRNA PCAT-1 in gastrointestinal cancers: A meta-analysis.

Authors:  Wanwei Liu; Jiwei Xu
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

2.  Long non-coding RNA GLIDR accelerates the tumorigenesis of lung adenocarcinoma by miR-1270/TCF12 axis.

Authors:  Guigang Tai; Hongyi Fu; Hongzhong Bai; Hui Liu; Lijuan Li; Tao Song
Journal:  Cell Cycle       Date:  2021-08-07       Impact factor: 5.173

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.